CSF2 and neoplasm: These can be mitigated by arming OVs with immunostimulatory cytokines (e.g., GM-CSF, IL-12), sequencing therapy to support viral replication and T-cell priming, and employing intratumoral delivery or carrier cells to enhance tumor localization [146].